Welcome to the UPF Digital Repository

Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker

Show simple item record

dc.contributor.author Martínez Bosch, Neus
dc.contributor.author Barranco Priego, Luis Eugenio
dc.contributor.author Orozco, Carlos Alberto
dc.contributor.author Moreno, Mireia
dc.contributor.author Visa Turmo, Laura
dc.contributor.author Iglesias Coma, Mar
dc.contributor.author Oldfield, Lucy
dc.contributor.author Neoptolemos, John P.
dc.contributor.author Greenhalf, William
dc.contributor.author Earl, Julie
dc.contributor.author Carrato, Alfredo
dc.contributor.author Costello, Eithne
dc.contributor.author Navarro Medrano, Pilar
dc.date.accessioned 2019-06-27T07:33:50Z
dc.date.available 2019-06-27T07:33:50Z
dc.date.issued 2018
dc.identifier.citation Martinez-Bosch N, Barranco LE, Orozco CA, Moreno M, Visa L, Iglesias M. et al. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Oncotarget. 2018 Aug 31;9(68):32984-32996. DOI: 10.18632/oncotarget.26034
dc.identifier.issn 1949-2553
dc.identifier.uri http://hdl.handle.net/10230/41877
dc.description.abstract Pancreatic ductal adenocarcinoma (PDA) is the most frequent type of pancreatic cancer and one of the deadliest diseases overall. New biomarkers are urgently needed to allow early diagnosis, one of the only factors that currently improves prognosis. Here we analyzed whether the detection of circulating galectin-1 (Gal-1), a soluble carbohydrate-binding protein overexpressed in PDA tissue samples, can be used as a biomarker for PDA. Gal-1 levels were determined by ELISA in plasma from healthy controls and patients diagnosed with PDA, using three independent cohorts. Patients with chronic pancreatitis (CP) were also included in the study to analyze the potential of Gal-1 to discriminate between cancer and inflammatory process. Plasma Gal-1 levels were significantly increased in patients with PDA as compared to controls in all three cohorts. Gal-1 sensitivity and specificity values were similar to that of the CA19-9 biomarker (the only FDA-approved blood test biomarker for PDA), and the combination of Gal-1 and CA19-9 significantly improved their individual discriminatory powers. Moreover, high levels of Gal-1 were associated with lower survival in patients with non-resected tumors. Collectively, our data indicate a strong potential of using circulating Gal-1 levels as a biomarker for detection and prognostics of patients with PDA.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Impact Journal
dc.rights Copyright : © 2018 Martinez-Bosch et al. This article is distributed under the terms of the Creative Commons Attribution License (CC-BY), https://creativecommons.org/licenses/by/3.0/, which permits unrestricted use and redistribution provided that the original author and source are credited
dc.rights.uri https://creativecommons.org/licenses/by/3.0/
dc.title Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.18632/oncotarget.26034
dc.subject.keyword Biomarker
dc.subject.keyword Chronic pancreatitis
dc.subject.keyword Galectin-1
dc.subject.keyword Pancreatic cancer
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


In collaboration with Compliant to Partaking